Frost Radar : 항체약물접합체(ADC) 위탁개발생산(CDMO)(2025년)

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC revolution, which is transforming cancer treatment, is directly dependent on the capabilities of the specialized CDMOs profiled in this analysis. Understanding the strategies, strengths, and weaknesses of these players is essential for any stakeholder in the biopharmaceutical industry.

To succeed in this demanding environment, a CDMO must provide a comprehensive, end-to-end service offering. This includes capabilities in monoclonal antibody production, high-potency active pharmaceutical ingredient synthesis, advanced bioconjugation, and sterile fill-finish drug product manufacturing. These services must be supported by state-of-the-art facilities that require massive capital investment and an equally deep investment in the scientific and technical talent needed to manage these complex processes.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.

Table of Contents

Strategic Imperative and Growth Environment

Frost Radar™: Antibody-Drug Conjugate Contract Development and Manufacturing Organizations, 2025

Frost Radar™: Companies to Action

• Abzena
• Ajinomoto Bio-Pharma Services
• Axplora
• Catalent
• ChemExpress
• Lonza
• MabPlex
• Merck KGaA, Darmstadt, Germany
• Piramal Pharma Solutions
• Porton Pharma Solutions
• Recipharm
• Samsung Biologics
• Sterling Pharma Solutions
• Syngene International
• Thermo Fisher Scientific
• WuXi XDC

Best Practices & Growth Opportunities

• Best Practices
• Growth Opportunities

Frost Radar™ Analytics

Next Steps: Leveraging the Frost Radar™ to Empower Key Stakeholders

• Significance of Being on the Frost Radar™
• Frost Radar™ Empowers the CEO's Growth Team
• Frost Radar™ Empowers Investors
• Frost Radar™ Empowers Customers
• Frost Radar™ Empowers the Board of Directors

Legal Disclaimer